Current research on opioid receptor function

Current Drug Targets

Volumn 13, Issue 2, 2012, Pages 230-246

  Feng, Yuan ^a,e   He, Xiaozhou ^b   Yang, Yilin ^b   Chao, Dongman ^a,c   Lazarus, Lawrence H ^d   Xia, Ying ^a,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^e THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Brain; Function; Heart; Hibernation; Hypoxia; Ionic homeostasis; Ischemia; Lung; Neuroprotection; Neurotransmitters; Opioid receptors; Opioids; Pain

Indexed keywords

1,2,3,4,4A,5,12,12AALPHA OCTAHYDRO 4AALPHA (3 HYDROXYPHENYL) 2 METHYLQUINOLINO[2,3 G]ISOQUINOLINE; 3,4 DICHLORO N [1 ISOPROPYL 2 (1 PYRROLIDINYL)ETHYL] N METHYLBENZENEACETAMIDE; 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL] N,N DIETHYLBENZAMIDE; ADENYLATE CYCLASE; BREMAZOCINE; BRL 52537; CYCLIC AMP; DELTA OPIATE RECEPTOR; DELTORPHIN; DYNORPHIN A; ENADOLINE; ENKEPHALIN[2 DEXTRO ALANINE 5 DEXTRO LEUCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; ETORPHINE; GUANINE NUCLEOTIDE BINDING PROTEIN; KAPPA OPIATE RECEPTOR; KETAZOCINE; LEUCINE ENKEPHALIN[2 DEXTRO SERINE 6 THREONINE]; MU OPIATE RECEPTOR; N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZO[B]THIOPHENE 4 ACETAMIDE; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NALFURAFINE; OPIATE; OPIATE AGONIST; OPIATE RECEPTOR; PENTAZOCINE; SALVINORIN A; SPIRADOLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADDICTION; CELL PROLIFERATION; DRUG ABUSE; DRUG DEPENDENCE; EMOTION; HIBERNATION; HOMEOSTASIS; HUMAN; MEDICAL RESEARCH; NEUROPROTECTION; NONHUMAN; OBESITY; PAIN; PATHOPHYSIOLOGY; REVIEW; SEIZURE; SIGNAL TRANSDUCTION;

ANALGESICS, OPIOID; ANIMALS; CARDIOTONIC AGENTS; HEART; HUMANS; NEURONS; NEUROPROTECTIVE AGENTS; RECEPTORS, OPIOID;

EID: 84863171993     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012799201612     Document Type: Review

References (315)

1. Hosobuchi Y, Baskin DS, Woo SK. Reversal of induced ischemic neurologic deficit in gerbils by the opiate antagonist naloxone. Science 1982; 215(4528): 69-71.
2. Adams HP Jr, Olinger CP, Barsan WG, et al. A dose-escalation study of large doses of naloxone for treatment of patients with acute cerebral ischemia. Stroke 1986; 17(3): 404-409.
3. Skarphedinsson JO, Thoren P. Endorphin mechanisms are responsible for the beneficial effects of opioid antagonists on cerebral function during relative cerebral ischaemia in rats. Acta Physiologica Scandinavica 1988; 132(3): 281-288.
4. Olinger CP, Adams HP Jr, Brott TG, et al. High-dose intravenous naloxone for the treatment of acute ischemic stroke. Stroke 1990; 21(5): 721-725.
5. Hayward NJ, McKnight AT, Woodruff GN. Neuroprotective effect of the kappa-agonist enadoline (CI-977) in rat models of focal cerebral ischaemia. Eur J Neurosci 1993; 5(7): 961-967.
6. Mayfield KP, D'Alecy LG. Delta-1 opioid agonist acutely increases hypoxic tolerance. J Pharmacol Exp Ther 1994; 268(2): 683-688.
7. Endoh H, Taga K, Yamakura T, et al. Effects of naloxone and morphine on acute hypoxic survival in mice. Crit Care Med 1999; 27(9): 1929-1933.
8. Zhang JH, Xia Y, Haddad GG. Activation of delta-opioid receptors protects cortical neurons from glutamate excitotoxic injury. Soc Neurosci 1999; 28: Abstract 736.
9. Zhang JH, Haddad GG, Xia Y. Delta-, but not mu- and kappaopioid receptor activation protects neocortical neurons from glutamate-induced excitotoxic injury. Brain Res 2000; 885(2): 143-153.
10. Zhang JH, Gibney GT, Xia Y. Effect of prolonged hypoxia on expression of Na+ channel mRNA subtypes in the developing rat cortex. Brain Res Mol Brain Res 2001; 91(1-2): 154-158.
11. Zhang JH, Gibney GT, Xia Y. Neuroprotective role of delta-opioid receptors in cortical neurons. Am J Physiol Cell Physiol 2002; 282(6): C1225-C1234.
12. Zhang J, Qian H, Zhao P, Hong SS, Xia Y. Rapid hypoxia preconditioning protects cortical neurons from glutamate toxicity through δ-opioid receptor. Stroke 2006; 37(4): 1094-1099.
13. Ma MC, Qian H, Ghassemi F, Zhao P, Xia Y. Oxygen sensitive δ- opioid receptor-regulated survival and death signals: novel insights into neuronal preconditioning and protection. J Biol Chem 2005; 280(16): 16208-16218.
14. Tian XS, Zhou F, Yang R, Xia Y, Wu GC, Guo JC. Effects of intracerebroventricular injection of delta-opioid receptor agonist TAN-67 or antagonist naltrindole on acute cerebral ischemia in rat. Acta Physiol Sin 2008; 60(4): 475-484.
15. Yang Y, Xia X, Zhang Y, et al. Delta-opioid receptor activation attenuates oxidative injury in the ischemic rat brain. BMC Biol 2009; 7: 55.
16. Chao D, Xia Y. Ionic storm in hypoxic/ischemic stress: can opioid receptors subside it? Prog Neurobiol 2010; 90(4): 439-470.
17. Feng Y, He X, Yang Y, Chen J, Yin K, Xia Y. Effect of deltaopioid receptor over-expression on cortical expression of GABAA receptor alpha1-subunit in hypoxia. Chin J Physiol 2011; 54(2): 118-123.
18. Lim YJ, Zheng S, Zuo Z. Morphine preconditions purkinje cells against cell death under in vitro simulated ischemia-reperfusion conditions. Anesthesiology 2004; 100(3): 562-568.
19. Horiuchi T, Kawaguchi M, Sakamoto T, et al. The effects of the delta-opioid agonist SNC80 on hind-limb motor function and neuronal injury after spinal cord ischemia in rats. Anesth Analg 2004; 99(1): 235-240.
20. Horiuchi T, Kawaguchi M, Kurita N, et al. Effects of delta-opioid agonist SNC80 on white matter injury following spinal cord ischemia in normothermic and mildly hypothermic rats. J Anesth 2008; 22(1): 32-37.
21. Borlongan CV, Wang Y, Su TP. Delta opioid peptide (D-Ala2,DLeu5) enkephalin: linking hibernation and neuroprotection. Front Biosci 2004; 9: 3392-3398.
22. Borlongan CV, Hayashi T, Oeltgen PR, Su TP, Wang Y. Hibernation-like state induced by an opioid peptide protects against experimental stroke. BMC Biol 2009; 7: 31.
23. Zhao P, Huang Y, Zuo Z. Opioid preconditioning induces opioid receptor-dependent delayed neuroprotection against ischemia in rats. J Neuropathol Exp Neurol 2006; 65(10): 945-952.
24. Su DS, Wang ZH, Zheng YJ, Zhao YH, Wang XR. Dosedependent neuroprotection of delta opioid peptide [D-Ala2,DLeu5] enkephalin in neuronal death and retarded behavior induced by forebrain ischemia in rats. Neurosci Lett 2007; 423(2): 113-117.
25. Iwata M, Inoue S, Kawaguchi M, Nakamura M, Konishi N, Furuya H. Effects of delta-opioid receptor stimulation and inhibition on hippocampal survival in a rat model of forebrain ischaemia. Br J Anaesth 2007; 99(4): 538-546.
26. Charron C, Messier C, Plamondon H. Neuroprotection and functional recovery conferred by administration of kappa- and delta- opioid agonists in a rat model of global ischemia. Physiol Behav 2008; 93(3): 502-511.
27. Kao TK, Ou YC, Liao SL, Chen WY, Wang CC, Chen SY, Chiang AN, Chen CJ. Opioids modulate post-ischemic progression in a rat model of stroke. Neurochem 2008; 52(6): 1256-1265.
28. Govindaswami M, Brown SA, Yu J, et al. Delta 2-specific opioid receptor agonist and hibernating woodchuck plasma fraction provide ischemic neuroprotection. Acad Emerg Med 2008; 15(3): 250-257.
29. Pamenter ME, Buck LT. δ-Opioid receptor antagonism induces NMDA receptor-dependent excitotoxicity in anoxic turtle cortex. J Exp Biol 2008; 211(21): 3512-3517.
30. Peng PH, Huang HS, Lee YJ, Chen YS, Ma MC. Novel role for the δ-opioid receptor in hypoxic preconditioning in rat retinas. J Neurochem 2009; 108(3): 741-754.
31. Zhu M, Li M, Tian X, Ou X, Zhu C, Guo J. Neuroprotective role of δ-opioid receptors against mitochondrial respiratory chain injury. Brain Res 2009; 1252: 183-191.
32. Law PY, Loh HH. Regulation of Opioid Receptor Activities. J Pharmacol Exp Ther 1999; 289(2): 607-624.
33. Wiesenfeld-Hallin Z, de Araúja Lucas G, Alster P, Xu XJ, Hökfelt T. Cholecystokinin/opioid interactions. Brain Res 1999; 848(1-2): 78-89.
34. Pasternak GW. Multiple opiate receptors: déjà vu all over again. Neuropharmacology 2004; 47(Suppl 1): 312-223.
35. Waldhoer M, Bartlett SE, Whistler JL. Opioid receptors. Annu Rev Biochem 2004; 73: 953-990.
36. Barry U, Zuo Z. Opioids: old drugs for potential new applications. Curr Pharm Des 2005; 11(10): 1343-1350.
37. Bohn LM, Raehal KM. Opioid receptor signaling: relevance for gastrointestinal therapy. Curr Opin Pharmacol 2006; 6(6): 559-563.
38. Ananthan S. Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics. AAPS J 2006; 8(1): E118-E125.
39. Lambert DG. The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential. Nature Rev Durg Disc 2008; 7(8): 694-711.
40. Kieffer BL, Evans CJ. Opioid receptors: from binding sites to visible molecules in vivo. Neuropharmacology 2009; 56(Suppl 1): 205-212.
41. Kreek MJ, Zhou Y, Butelman ER, Levran O. Opiate and cocaine addiction: from bench to clinic and back to the bench. Curr Opin Pharmacol 2009; 9(1): 74-80.
42. Feng Y, Chao D, He X, et al. A novel insight into neuroprotection against hypoxic/ischemic stress. Acta Physiol Sin 2009; 61(6): 585-592.
43. Zhao P, Guo JC, Xia Y, et al. Electro-acupuncture and brain protection from cerebral ischemia: the role of delta-opioid receptor. Soc Neurosci Abstract Program 2002; No. 490.13.
44. Martin WR. Opioid antagonists. Pharmacol Rev 1967; 19(4): 463-521.
45. Tsou K, Jang CS. Studies on the site of analgesic action of morphine by intracerebral micro-injection. Sci Sin 1964; 13: 1099-1109.
46. Pert A, Yaksh T. Sites of morphine induced analgesia in the primate brain: relation to pain pathways. Brain Res 1974; 80(1): 135-140.
47. Pert A, Yaksh T. Localization of the antinociceptive action of morphine in primate brain. Pharmacol Biochem Behav 1975; 3(1): 133-138.
48. Mayer D, Liebeskind JC. Pain reduction by focal electrical stimulation of the brain: an anatomical and behavioral analysis. Brain Res 1974; 68(1): 73-93.
49. Akil H, Mayer DJ, Liebeskind JC. Antagonism of stimulationproduced analgesia by naloxone, a narcotic antagonist. Science 1976; 191(4230): 961-962.
50. Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morgan BA, Morris HR. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature 1975; 258(5536): 577-579.
51. Snyder SH, Matthysse S. Opiate Receptor Mechanisms. Neurosci Res Program Bull 1975; 13(1): 1-66.
52. Li CH, Chung D, Doneen BA. Isolation, characterization and opiate activity of beta-endorphin from human pituitary glands. Biochem Biophys Res Commun 1976; 72(4): 1542-1547.
53. Doneen BA, Chung D, Yamashiro D, Law PY, Loh HH, Li CH. Beta-Endorphin: structure-activity relationships in the guinea pig ileum and opiate receptor binding assays. Biochem Biophys Res Commun 1977; 74(2): 656-662.
54. Goldstein A, Tachibana S, Lowney LI, Hunkapiller M, Hood L. Dynorphin-(1-13), an extraordinarily potent opioid peptide. Proc Natl Acad Sci USA 1979; 76(12): 6666-6670.
55. Mollereau C, Parmentier M, Mailleux P, et al. ORL1, a novel member of the opioid receptor family: cloning, functional expression and localization. FEBS Lett 1994; 341(1): 33-38.
56. Meunier JC, Mollereau C, Toll L, et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 1995; 377(6549): 532-535.
57. Reinscheid RK, Nothacker HP, Bourson A, et al. Orphanin FQ: a neuropeptide that activates an opioid like G protein-coupled receptor. Science 1995; 270(5237): 792-794.
58. Zadina JE, Hackler L, Ge L-J, Kastin AJ. A potent and selective endogenous agonist for the mu-opiate receptor. Nature 1997; 386(6624): 499-502.
59. Hackler L, Zadina JE, Ge L-J, Kastin AJ. Isolation of relatively large amounts of endomorphin-1 and endomorphin-2 from human brain cortex. Peptides 1997; 18(10): 1635-1639.
60. Höllt V. Precursors of opioid peptides and their gene regulation. Clin Neuropharmacol 1992; 15(Suppl 1 Pt A): 50A-51A.
61. Li CH, Chung D. Primary structure of human δ-lipotropin. Nature 1976; 260(5552): 622-624.
62. Comb M, Seeburg PH, Adelman J, Eiden L, Herbert E. Primary structure of the human met- and leu-enkephalin precursor and its mRNA. Nature 1982; 295(5851): 663-666.
63. Barr JM, Van Stipdonk MJ. Multi-stage tandem mass spectrometry of metal cationized leucine enkephalin and leucine enkephalin amide. Rapid Commun Mass Spectrom 2002; 16(6): 566-578.
64. Martin WR. Pharmacology of opioids. Pharmacol Rev 1983; 35(4): 283-323.
65. Paterson SJ, Robson LE, Kosterlitz HW. Classification of opioid receptors. Br Med Bull 1983; 39(1): 31-36.
66. Zöllner C, Schäfer M. Opioids in anesthesia. Anaesthesist 2008; 57(7): 729-740.
67. Zöllner C, Stein C. Opioids. Handb Exp Pharmacol 2007; 177: 31-63.
68. Mansour A, Fox CA, Akil H, Watson SJ. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci 1995; 18(1): 22-29.
69. Vogt BA, Wiley RG, Jensen EL. Localization of mu and delta opioid receptors to anterior cingulated afferents and projection neurons and input/output model of mu regulation. Exp Neurol 1995; 135(2): 83-92.
70. Xia Y, Haddad GG. Ontogeny and distribution of opioid receptors in the rat brainstem. Brain Res 1991; 549(2): 181-193.
71. Xia Y, Haddad GG. Major difference in the expression of deltaand mu-opioid receptors between turtle and rat brain. J Comp Neurol 2001; 436(2): 202-210.
72. Abbadie C, Pan YX, Pasternak GW. Immunohistochemical study of the expression of exon11-containing mu opioid receptor variants in mouse brain. Neuroscience 2004; 127(2): 419-430.
73. Beadles-Bohling AS, Wiren KM. Alteration of kappa-opioid receptor system expression in distinct brain regions of a genetic model of enhanced ethanol withdrawal severity. Brain Res 2005; 1046(1-2): 77-89.
74. Wittert G, Hope P, Pyle D. Tissue distribution of opioid receptor gene expression in the rat. Biochem Biophys Res Commun 1996; 218(3): 877-881.
75. Villemagne PS, Dannals RF, Ravert HT, Frost JJ. PET imaging of human cardiac opioid receptors. Eur J Nucl Med Mol Imaging 2002; 29(10): 1385-1388.
76. Darland T, Heinricher MM, Grandy DK. Orphanin FQ/ nociceptin: a role in pain and analgesia, but so much more. Trends Neurosci 1998; 21(5): 215-221.
77. Meis S. Nociceptin/orphanin FQ: actions within the brain. Neuroscientist 2003; 9(2): 158-168.
78. Heinricher MM. Nociceptin/orphanin FQ: pain, stress and neural circuits. Life Sci 2005; 77(25): 3127-3132.
79. Rizzi A, Nazzaro C, Marzola GG, et al. Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: pharmacological and genetic evidences. Pain 2006; 124(1-2): 100-108.
80. Reiss D, Wichmann J, Tekeshima H, Kieffer BL, Ouagazzal AM. Effects of nociceptin/orphanin FQ receptor (NOP) agonist, Ro64-6198, on reactivity to acute pain in mice: comparison to morphine. Eur J Pharmacol 2008; 579(1-3): 141-148.
81. Scoto GM, Aricò G, Ronsisvalle S, Parenti C. Blockade of the nociceptin/orphanin FQ/NOP receptor system in the rat ventrolateral periaqueductal gray potentiates DAMGO analgesia. Peptides 2007; 28(7): 1441-1446.
82. Chen Y, Somme C. Activation of the nociceptin opioid system in rat sensory neurons produces antinociceptive effects in inflammatory pain: involvement of inflammatory mediators. J Neurosci Res 2007; 85(7): 1478-1488.
83. Stevens CW, Brasel CM, Mohan S. Cloning and bioinformatics of amphibian mu, delta, kappa, and nociceptin opioid receptors expressed in brain tissue: evidence for opioid receptor divergence in mammals. Neurosci Lett 2007; 419(3): 189-1894.
84. Doggrell SA. Cardiovascular and renal effects of nociceptin/orphanin FQ: a new mediator to target? Curr Opin Investig Drugs 2007; 8(9): 742-749.
85. Zhang S, Yekkirala A, Tang Y, Portoghese PS. A bivalent ligand (KMN-21) antagonist for mu/kappa heterodimeric opioid receptors. Bioorg Med Chem Lett 2009; 19(24): 6978-6980.
86. Garzon J, Jen M, Sanchez-Blazquez P, Lee N. Dynorphin (1-13), along-lasting inhibitor of opiate receptor binding in vitro. Life Sci 1982; 31(16-17): 1789-1792.
87. Demoliou-Mason CD, Barnard EA. Distinct subtypes of the opioid receptor with allosteric interactions in brain membranes. J Neurochem 1986; 46(4): 1118-1128.
88. Miaskowski C, Taiwo Y, Levine J. Kappa- and delta-opioid agonists synergize to produce potent analgesia. Brain Res 1990; 509(1): 165-168.
89. Dawson-Basoa M, Gintzler AR. Gestational and ovarian sex steroid antinociception: synergy between spinal kappa and delta opioid systems. Brain Res 1998; 794(1): 61-67.
90. Gackenheimer SL, Suter TM, Pintar JE, et al. Localization of opioid receptor antagonist [3H]-LY255582 binding sites in mouse brain: comparison with the distribution of mu, delta and kappa binding sites. Neuropeptides 2005; 39(6): 559-567.
91. Fujita Y, Tsuda Y, Li T, et al. Development of potent bifunctional endomorphin-2 analogues with mixed mu-/delta-opioid agonist and delta-opioid antagonist properties. J Med Chem 2004; 47(14): 3591-3519.
92. Balboni G, Onnis V, Cenzo C, et al. Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem 2006; 49(18): 5610-5617.
93. Traynor J. Trends. Subtypes of k-opioid receptor: fact or fiction? Trends Pharmacol Sci 1989; 10(2): 52-53.
94. Traynor J, Elliot J. δ-opioid receptor subtypes and cross talk with μ-receptors. Trends Pharmacol Sci 1993; 14(3): 84-85.
95. Borsodi A, Tóth G. Characterization of opioid receptor types and subtypes with new ligands. Ann NY Acad Sci 1995; 757: 339-352.
96. Zaki PA, Bilsky EJ, Vanderah TW, Lai J, Evans CJ, Porreca F. Opioid receptor types and subtypes: the delta receptor as a model. Annu Rev Pharmacol Toxicol 1996; 36: 379-401.
97. Wolozin BL, Pasternak GW. Classification of multiple morphine and enkephalin binding sites in the central nervous system. Proc Natl Acad Sci USA 1981; 78(10): 6181-6185.
98. Clark JA, Liu L, Price M, Hersh B, Edelson M, Pasternak GW. Kappa opiate receptor multiplicity: evidence for two U50, 488-sensitive kappa 1 subtypes and a novel kappa 3 subtype. J Pharmacol Exp Ther 1989; 251(2): 461-468.
99. Butelman ER, Ko MC, Sobczyk-Kojiro K, et al. Kappa-Opioid Receptor Binding Populations in Rhesus Monkey Brain: relationship to an Assay of Thermal Antinociception. J Pharmacol Exp Ther 1998; 285(2): 595-601.
100. Caudle RM, Finegold AA, Mannes AJ, Tobias MD, Kenshalo DR, Iadarola MJ. Spinal kappa1 and kappa2 opioid binding sites in rats, guinea pigs, monkeys and humans. Neuroreport 1998; 9(11): 2523-2525.
101. Jiang Q, Takemori AE, Sultana M, et al. Differential antagonism of opioid delta antinociception by [D-Ala2,Leu5,Cys6]enkephalin and naltrindole 5'-isothiocyanate: evidence for delta receptor subtypes. J Pharmacol Exp Ther 1991; 257(3): 1069-1075.
102. Sofuoglu M, Portoghese PS, Takemori AE. Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: evidence for delta opioid receptor subtypes. J Pharmacol Exp Ther 1991; 257(2): 676-680.
103. Sofuoglu M, Portoghese PS, Takemori AE. 7-Benzylidenenaltrexone (BNTX): A selective δ1 opioid receptor antagonist in the mouse spinal cord. Life Sci 1993; 52(8): 769-775.
104. Mattia A, Vanderah T, Mosberg HI, Porreca F. Lack of antinociceptivecross- tolerancebetween [D-Pen2,DPen5] enkephalin and [D-Ala2] deltorphin II in mice: evidence for delta receptor subtypes. J Pharmacol Exp Ther 1991; 258(2): 583-587.
105. Rothman RB, Bowen WD, Herkenham M, Jacobson AE, Rice KC, Pert CB. A Quantitative study of [3H]D-Ala2-D-Leu5-enkephalin binding to rat brain membranes. Evidence that oxymorphone is a noncompetitive inhibitor of the lower affinity delta-binding site. Mol Pharmacol 1985; 27(3): 399-409.
106. Rothman RB, Bowen WD, Bykov V, et al. Preparation of rat brain membranes greatly enriched with either type-I-delta or type-II-delta opiate binding sites using site directed alkylating agents: evidence for a two-site allosteric model. Neuropeptides 1984; 4(3): 201-215.
107. Rothman RB, Bykov V, Jacobson AE, Rice KC, Long JE, Bowen WD. A study of the effect of the irreversible delta receptor antagonist [D-Ala2,Leu5,Cys6]-enkephalin on delta cx and delta ncx opioid binding sites in vitro and in vivo. Peptides 1992; 13(4): 691-694.
108. Giros B, Pohl M, Rochelle JM, Seldin MF. Chromosomal localization of opioid peptide and receptor genes in the mouse. Life Sci 1995; 56(18): PL369-PL375.
109. Liang Y, Mestek A, Yu L, Carr LG. Cloning and characterization of the promoter region of the mouse mu opioid receptor gene. Brain Res 1995; 679(1): 82-88.
110. Jordan BA, Cvejic S, Devi LA. Opioids and their Complicated Receptor Complexes. Neuropsychopharmacology 2000; 23(4 Suppl): S5-18.
111. Evans CJ, Keith DE, Morrison H, Magendzo K, Edwards RH. Cloning of a delta opioid receptor by functional expression. Science 1992; 258(5090): 1952-1955.
112. Kieffer BL, Befort K, Gaveriaux-Ruff C, Hirth CG. The deltaopioid receptor: isolation of a cDNA clone by expression cloning and pharmacological characterization. Proc Natl Acad Sci USA 1992; 89(24): 12048-12052.
113. Augustin LB, Felsheim RF, Min BH, Fuchs SM, Fuchs JA, Loh HH. Genomic structure of the mouse delta opioid receptor gene. Biochem Biophys Res Commun 1995; 207(1): 111-119.
114. Chen Y, Mestek A, Liu J, Yu L. Molecular cloning of a rat kopioid receptor reveals sequence similarities to the m and d opioid receptors. Biochem J 1993; 295(pt3): 625-628.
115. Abood ME, Noel MA, Farnsworth JS, Tao Q. Molecular cloning and expression of a delta-opioid receptor from rat brain. J Neurosci Res 1994; 37(6): 714-719.
116. Simonin F, Befort K, Gaveriaux-Ruff C, et al. The human deltaopioid receptor: Genomic organization, cDNA cloning, functional expression, and distribution in human brain. Mol Pharmacol 1994; 46(6): 1015-1021.
117. Pan L, Xu J, Yu R, Xu MM, Pan YX, Pasternak GW. Identification and characterization of six new alternatively spliced variants of the human mu opioid receptor gene. Neuroscience 2005; 133(1): 209-220.
118. Pasternak GW. Molecular biology of opioid analgesia. J Pain Symptom Manage 2005; 29(5 Suppl): S2-S9.
119. Shimohigashi Y, Takano, Kamiya H, Costa T, Herz A, Stammer CH. A highly selective ligand for brain delta opiate receptors, acyclopropyl(E)Phe(4)-enkephalin analog, suppresses mu receptormediated thermal analgesia by morphine. FEBS Lett 1988; 233 (2): 289-293.
120. Jin W, Lee NM, Loh HH, Thayer SA. Dual excitatory and inhibitory effects of opioids on intracellular calcium in neuroblastoma x glioma hybrid NG108-15 cells. Mol Pharmacol 1992; 42(6): 1083-1089.
121. Wang JF, Shun XJ, Yang HF, Ren MF, Han JS. Suppression by [DPen2, D-Pen5] enkephalin on cyclic AMP dependent protein kinase-induced, but not protein kinase C-induced increment of intracellular free calcium in NG108-15 cells. Life Sci 1993; 52(19): 1519-1525.
122. Vlaskovska M, Schramm M, Nylander I, et al. Opioid effects on 45Ca2+ uptake and glutamate release in rat cerebral cortex in primary culture. J Neurochem 1997; 68(2): 571-524.
123. Thorlin T, Eriksson PS, Persson PAI, Aberg ND, Hansson E, Rnnbäck L. Delta-opioid receptors on astroglial cells in primary culture: mobilization of intracellular free calcium via a pertussis sensitive G protein. Neuropharmacology 1998; 37(3): 299-311.
124. Spadoni F, Martella G, Martorana A, et al. Opioid-mediated modulation of calcium currents in striatal and pallidal neurons following resepine treatment: focus on kappa response. Synapse 2004; 51(3): 194-205.
125. Komai H, McDowell TS. Effects of local anesthetics on opioid inhibition of calcium current in rat dorsal root ganglion neurons. Neurosci Lett 2007; 418(3): 298-303.
126. Rola R, Jarkiewicz M, Szulczyk P. Modulation of Ca2+ channel current by δ opioid receptors in prefrontal cortex pyramidal neurons in rats. Acta Neurobiol Exp 2008; 68(1): 10-25.
127. Iegorova O, Fisyunov A, Krishtal O. G-protein-independent modulation of P-type calcium channels by mu-opioids in Purkinje neurons of rat. Neurosci Lett 2010; 480(2): 106-111.
128. Bao L, Jin SX, Zhang C, et al. Activation of delta opioid receptors induces receptor insertion and neuropeptide secretion. Neuron 2003; 37(1): 121-133.
129. Samways DSK, Henderson G. Opioid elevation of intracellular free calcium: possible mechanisms and physiological relevance. Cell Signal 2006; 18(2): 151-161.
130. Chao D, Qian H, Ghassemi F, Chen JS, Xia Y. Transgenic overexpression of δ-opioid receptors protects the cortex from anoxic disruption of ionic homeostasis. Soc Neurosci Abstract Program 2006; No. 87: 19/MM68.
131. Chao D, Bazzy-Asaad A, Balboni G, Xia Y. δ-, but not μ-,opioid receptor stabilizes K + homeostasis by reducing Ca2+ influx in the cortex during acute hypoxia. J Cell Physiol 2007a; 212(1): 60-67.
132. Chao D, Donnelly DF, Feng Y, Bazzy-Asaad A, Xia Y. Cortical dopioid receptors potentiate K+ homeostasis during anoxia and oxygen-glucose deprivation. J Cereb Blood Flow Metab 2007b; 27(2): 356-368.
133. Chao D, Bazzy-Asaad A, Balboni G, Salvadori S, Xia Y. Activation of DOR attenuates anoxic K+ derangement via inhibition of Na+ entry in mouse cortex. Cereb Cortex 2008; 18(9): 2217-2227.
134. Chao D, Balboni G, Lazarus LH, Salvadori S, Xia Y. Na+ mechanism of δ-opioid receptor induced protection from anoxic K+ leakage in the cortex. Cell Mol Life Sci 2009; 66(6): 1105-1115.
135. Kang X, Chao D, Gu Q, et al. δ-opioid receptors protect from anoxic disruption of Na+ homeostasis via Na+ channel regulation. Cell Mo Life Sci 2009; 66(21): 3505-3516.
136. Balboni G, Salvadori S, Guerrini R, et al. Potent delta-opioid agonists containing the Dmt-Tic pharmacophore. J Med Chem 2002; 45(25): 5556-5563.
137. Malendowicz LK, Rebuffat P, Tortorella C, Nussdorfer GG, Ziolkowska A, Hochol A. Effects of met-enkephalin on cell proliferation in different models of adrenocortical-cell growth. Int J Mol Med 2005; 15(5): 841-845.
138. Narita M, Kuzumaki N, Miyatake M, et al. Role of delta-opioid receptor function in neurogenesis and neuroprotection. J Neurochem 2006; 97(5): 1494-1505.
139. Donahue RN, McLaughlin PJ, Zagon IS. Cell proliferation of human ovarian cancer is regulated by the opioid growth factoropioid growth factor receptor axis. Am J Physiol Regul Integr Comp Physiol 2009; 296(6): R1716-R1725.
140. Avella DM, Kimchi ET, Donahue RN, et al. The opioid growth factor-opioid growth factor receptor axis regulates cell proliferation of human hepatocellular cancer. Am J Physiol Regul Integr Comp Physiol 2010; 298(2): R459-R466.
141. Hayward NJ, McKnight AT, Woodruff GN. Neuroprotective effect of the kappa-agonist enadoline (CI-977) in rat models of focal cerebral ischaemia. Eur J Neurosc 1993; 5(7): 961-967.
142. Summers RL, Li Z, Hildebrandt D. Effect of a delta receptor agonist on duration of survival during hemorrhagic shock. Acad Emerg Med 2003; 10(6): 587-593.
143. Yang L, Wang H, Shah K, Karamyan VT, Abbruscato TJ. Opioid receptor agonists reduce brain edema in stroke. Brain Res 2011; 1383: 307-316.
144. Chen CJ, Cheng FC, Liao SL, Chen WY, Lin NN, Kuo JS. Effects of naloxone on lactate, pyruvate metabolism and antioxidant enzyme activity in rat cerebral ischemia/reperfusion. Neurosci Lett 2000; 287(2): 113-116.
145. Chen CJ, Liao SL, Chen WY, Hong JS, Kuo JS. Cerebral ischemia/reperfusion injury in rat brain: effects of naloxone. Neurorepor 2001; 12(6): 1245-1249.
146. Tian XS, Zhou F, Yang R, Xia Y, Wu GC, Guo JC. Electroacupuncture protects the brain against acute ischemic injury via up-regulation of delta-opioid receptor in rats. J Chin Integr Med 2008b; 6(6): 632-638.
147. Tian XS, Zhou F, Yang R, Xia Y, Wu GC, Guo JC. Role of δ-opioid receptors in cumulative electro-acupuncture induced protection from ischemic injury in the rat brain. Shanghai J TCM 2008; 42: 71-74.
148. Bruce DS, Bailey EC, Setran DP, et al. Circannual variations in bear plasma albumin and its opioid-like effects on guinea pig ileum. Pharmacol Biochem Behav 1996; 53(4): 885-889.
149. Bourhim N, Kabine M, Elkebbaj MS. Characterization of opioid peptides and opioid receptors in the brain of jerboa (Jaculus orientalis), a hibernating rodent. Brain Res Bull 1997; 44(5): 615-620.
150. Peart JN, Gross ER, Gross GJ. Opioid-induced preconditioning: recent advances and future perspectives. Vascul Pharmacol 2005; 42(5-6): 211-218.
151. Wu T, Dong P, Chen C, Yang J, Hou X. The myocardial protection of polarizing cardioplegia combined with delta-opioid receptor agonist in swine. Ann Thorac Surg 2011; 91(6): 1914-1920.
152. Cui Y, Lee TF, Wang LC. State-dependent changes of brain endogenous opioids in mammalian hibernation. Brain Res Bull 1996; 40(2): 129-133.
153. Ye ZC, Cai YP. Changes of opioid contents in brain and plasma through the hibernation bout cycle of ground squirrels. Acta Physiol Sinica 1995; 47(6): 610-614.
154. Nurnberger F, Lee TF, Jourdan ML, Wang LC. Seasonal changes in methionine-enkephalin immunoreactivity in the brain of a hibernator, Spermophilus columbianus. Brain Res 1991; 547(1): 115-121.
155. Yu LC, Cai YP. Arousal following intra-preoptic area administration of naltrexone, ICI 174864 or nor-BNI in hibernating ground squirrels. Behav Brain Res 1993; 57(1): 31-35.
156. Kieffer BL, Gavériaux-Ruff C. Exploring the opioid system by gene knockout. Prog Neurobiol 2002; 66(5): 285-306.
157. Eisinger DA, Schulz R. Mechanism and consequences of deltaopioid receptor internalization. Crit Rev Neurobiol 2005; 17(1): 1-26.
158. Hanlon KE, Herman DS, Agnes RS, et al. Novel peptide ligands with dual acting pharmacophores designed for the pathophysiology of neuropathic pain. Brain Res 2011; 1395: 1-11.
159. Molina PE. Stress-specific opioid modulation of haemodynamic counter-regulation. Clin Exp Pharmacol Physiol 2002; 29(3): 248-253.
160. Troullos E, Hargreaves KM, Dionne RA. Ibuprofen elevates immunoreactive beta-endorphin levels in humans during surgical stress. Clin Pharmacol Ther 1997; 62(1): 74-81.
161. Kho HG, Kloppenborg PW, van Egmond J. Effects of acupuncture and transcutaneous stimulation analgesia on plasma hormone levels during and after major abdominal surgery. Eur J Anaesthesiol 1993; 10(3): 197-208.
162. Ozarda Ilcol Y, Ozyurt G, Kilicturgay S, Uncu G, Ulus IH. The decline in serum choline concentration in humans during and after surgery is associated with the elevation of cortisol, adrenocorticotropic hormone, prolactin and beta-endorphin concentrations. Neurosci Lett 2002; 324(1): 41-44.
163. Yamada K, Nabeshima T. Stress-induced behavioral responses and multiple opioid systems in the brain. Behav Brain Res 1995; 67(2): 133-145.
164. LaBuda CJ, Sora I, Uhl GR, Fuchs PN. Stress-induced analgesia in mu-opioid receptor knockout mice reveals normal function of the delta-opioid receptor system. Brain Res 2000; 869(1-2): 1-5.
165. Gavériaux-Ruff C, Kieffer BL. Opioid receptor genes inactivated in mice: the highlights. Neuropeptides 2002; 36(2-3): 62-71.
166. Matthes HW, Maldonado R, Simonin F, et al. Loss of morphineinduced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 1996; 383(6603): 819-823.
167. Yamada H, Shimoyama N, Sora I, et al. Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors. Brain Res 2006; 1083(1): 61-69.
168. Fristad I, Berggreen E, Haug SR. Delta opioid receptors in small and medium-sized trigeminal neurons supporting the dental pulp of rats. Arch Oral Biol 2006; 51(4): 273-281.
169. Patwardhan AM, Berg KA, Akopain AN, et al. Bradykinin-Induced functional competence and trafficking of the δ-opioid receptor in trigeminal nociceptors. J Neurosci 2005; 25(39): 8825-8832.
170. Zhu Y, King MA, Schuller AGP, et al. Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. Neuron 1999; 24(1): 243-252.
171. Scherrer G, Imamachi N, Cao YQ, et al. Dissociation of the opioid receptor mechanisms that control mechanical and heat pain. Cell 2009; 137(6): 1148-1159.
172. Wang GY, Wu S, Pei JM, Yu XC, Wong TM. Kappa- but not delta-opioid receptors mediate effects of ischemic preconditioning on both infarct and arrhythmia in rats. Am J Physiol Heart Circ Physiol 2001; 280(1): H384-H3891.
173. Gebhart GF. J.J. Bonica lecture-2000: Physiology, pathophysiology, and pharmacology of visceral pain. Reg Anesth Pain Med 2000; 25(6): 632-638.
174. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 1999; 286(5449): 2495-2498.
175. Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ, Caron MG. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 2000; 408(6813): 720-723.
176. Bohn LM, Lefkowitz RJ, Caron MGJ. Differential mechanisms of morphine antinociceptive tolerance revealed in (beta) arrestin-2 knock-out mice. J Neurosci Neurosci 2002; 22(23): 10494-10500.
177. Bohn LM, Gainetdinov RR, Sotnikova TD, et al. Enhanced rewarding properties of morphine, but not cocaine, in beta (arrestin)-2 knock-out mice. J Neurosci 2003; 23(32): 10265-10273.
178. Cen B, Yu Q, Guo J, et al. Direct binding of beta-arrestins to two distinct intracellular domains of the delta opioid receptor. J Neurochem 2001; 76(6): 1887-1894.
179. Xiang B, Yu GH, Guo J, et al. Heterologous activation of protein kinase C stimulates phosphorylation of delta-opioid receptor at serine 344, resulting in beta-arrestin- and clathrin-mediated receptor internalization. J Biol Chem 2001; 276(7): 4709-4716.
180. Kang J, Shi Y, Xiang B, et al. A nuclear function of beta-arrestin1 in GPCR signaling: regulation of histone acetylation and gene transcription. Cell 2005; 123(5): 833-847.
181. Zhang X, Wang F, Chen X, et al. Beta-arrestin1 and beta-arrestin2 are differentially required for phosphorylation-dependent and - independent internalization of delta-opioid receptors. J Neurochem 2005; 95(1): 169-1678.
182. Cunha-Oliveira T, Rego AC, Oliveira CR. Cellular and molecular mechanisms involved in the neurotoxicity of opioid and psychostimulant drugs. Brain Res Rev 2008; 58(1): 192-208.
183. LaLumiere RT, Kalivas PW. Glutamate release in the nucleus accumbens core is necessary for heroin seeking. J Neurosci 2008; 28(12): 3170-3177.
184. Birnbaum HG, White AG, Reynolds JL, et al. Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective. Clin J Pain 2006; 22(8): 667-676.
185. Karow A, Verthein U, Krausz M, Schafer I. Association of personality disorders, family conflicts and treatment with quality of life in opiate addiction. Eur Addict Res 2008; 14(1): 38-46.
186. Ivanov IS, Schulz KP, Palmero RC, Newcorn JH. Neurorobiology and evidence-based biological treatments for substance abuse disorders. CNS Spectr 2006; 11(11): 864-877.
187. Koch T, Höllt V. Role of receptor internalization in opioid tolerance and dependence. Pharmacol Ther 2008; 117(2): 199-206.
188. Christie MJ. Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br J Pharmacol 2008; 154(2): 384-396.
189. Przewlocki R. Opioid abuse and brain gene expression. Eur J Pharmacol 2004; 500(1-3): 331-349.
190. Harrison LM, Kastin AJ, Zadina JE. Opiate tolerance and dependence: receptors, G-proteins, and antiopiates. Peptides 1998; 19(9): 1603-1630.
191. Kreek MJ, Nielsen DA, LaForge KS. Genes associated with addiction: alcoholism, opiate, and cocaine addiction. Neuromolecular Med 2004; 5(1): 85-108.
192. Mayer P, Höllt V. Pharmacogenetics of opioid receptors and addiction. Pharmacogenet Genomics 2006; 16(1): 1-7.
193. Iskandar SB, Abi-Saleh BS, Mechleb BK, Fahrig SA. Methadone and torsade de pointes: case report and review of the literature. Tenn Med 2007; 100(2): 35-37.
194. Compton WM, Volkow ND. Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend 2006; 83(Suppl 1): S4-S7.
195. Quaglio GL, Lugoboni F, Pajusco B, et al; GICS. Hepatitis C virus infection: prevalence, predictor variables and prevention opportunities among drug users in Italy. J Viral Hepat 2003; 10(5): 394-400.
196. Ordaz-Sanchez I, Weber RJ, Rice KC, et al. Chemotaxis of human and rat leukocytes by the delta-selective non-peptidic opioid SNC 80. Rev Latinoam Microbiol 2003; 45(1-2): 16-23.
197. Korolenko TA, Goncharova IA, Anterejkina LI, Levina OA, Korolenko CP. Influence of opiate addiction on liver cell damage of patients with viral hepatitis C. Alaska Med 2007; 49(2 Suppl): 75-78.
198. Filliol D, Ghozland S, Chluba J, et al. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 2000; 25(2): 195-200.
199. Saitoh A, Yoshikawa Y, Onodera K, Kamei J. Role of delta-opioid receptor subtypes in anxiety-related behaviors in the elevated plusmaze in rats. Psychopharmacology (Berl) 2005; 182(3): 327-334.
200. Torregrossa MM, Jutkiewicz EM, Mosberg HI, Balboni G, Watson SJ, Woods JH. Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats. Brain Res 2006; 1069(1): 172-181.
201. Naidu PS, Lichtman AH, Archer CC, May EL, Harris LS, Aceto MD. NIH 11082 produces anti-depressant-like activity in the mouse tail-suspension test through a delta-opioid receptor mechanism of action. Eur J Pharmacol 2007; 566(1-3): 132-136.
202. Zhang H, Shi YG, Woods JH, Watson SJ, Ko MC. Central kappaopioid receptor-mediated antidepressant-like effects of nor- Binaltorphimine: behavioral and BDNF mRNA expression studies. Eur J Pharmacol 2007; 570(1-3): 89-96.
203. Zubieta J-K, Ketter TA, Bueller JA, et al. Regulation of human affective responses by anterior cingulated and limbic δ-opioid neurotransmission. Arch Gen Psychiatry 2003; 60(11): 1145-1153.
204. Taracha E, Mierzejewski P, Lehner M, et al. Stress-opioid interactions: a comparison of morphine and methadone. Pharmacol Rep 2009; 61(3): 424-435.
205. Vien N, Gleason CA, Hays SL, McPherson RJ, Chavkin C, Juul SE. Effects of neonatal stress and morphine on kappa opioid receptor signaling. Neonatology 2009; 96(4): 235-243.
206. Pinsky C, Bose R, Frederickson RC. Mu- and delta-opioid modulation of electrically- induced epileptic seizures in mice. NIDA Res Monogr 1986; 75: 543-546.
207. Tortella FC, Robles L, Holaday JW. The anticonvulsant effects of DADLE are primarily mediated by activation of delta opioid receptors: interactions between delta and mu receptor antagonists. Life Sci 1985; 37(6): 497-503.
208. Tortella FC, Echevarria E, Robles L, Mosberg HI, Holaday JW. Anticonvulsant effects of mu (DAGO) and delta (DPDPE) enkephalins in rats. Peptides 1988; 9(5): 1177-1181.
209. Tortella FC, Long JB. Endogenous anticonvulsant substance in rat cerebrospinal fluid after a generalized seizure. Science 1985; 228(4703): 1106-1108.
210. Grecksch G, Becker A, Schroeder H, Höllt V. Involvement of delta-opioid receptors in pentylenetetrazol kindling development and kindling-related processes in rats. Naunyn. Schmiedebergs Arch Pharmacol 1999; 360(2): 151-156.
211. Yajima Y, Narita M, Takahashi-Nakano Y, et al. Effects of differential modulation of mu-, delta- and kappa-opioid systems on bicuculline- induced convulsions in the mouse. Brain Res 2000; 862(1-2): 120-126.
212. Bregola G, Zucchini, S, Frigati L, et al. Involvement of the neuropeptide orphanin FQ/nociceptin in kainate and kindling seizures and epileptogenesis. Epilepsia 2002; 43(Suppl 5): 18-19.
213. Feng Y, Chao DM, Li WM, Cao YX, Wang YQ, Wu GC. Inhibition of nociceptin/ orphanin FQ on penicillin-induced seizures in rats. Brain Res 2004; 1020(1-2): 214-219.
214. Bausch B, Garland JP, Yamada J. The delta opioid receptor agonist, SNC80, has complex, dose-dependent effects on pilocarpine-induced seizures in Sprague-Dawley rats. Brain Res 2005; 1045(1-2): 38-44.
215. Danielsson I, Gasior M, Stevenson GW, Folk JE, Rice KC, Negus SS. Electroencephalographic and convulsant effects of the delta opioid agonist SNC80 in rhesus monkeys. Pharmacol Biochem Behav 2006; 85(2): 428-434.
216. Solbrig MV, Adrian R, Baratta J, Lauterborn JC, Koob GF. Kappa opioid control of seizures produced by a virus in an animal model. Brain 2006; 129(pt3): 642-654.
217. Saboory E, Derchansky M, Ismaili M, et al. Mechanisms of morphine enhancement of spontaneous seizure activity. Anest Analg 2007; 105(6): 1729-1735.
218. Zhang HN, Ko MC. Seizure activity involved in the up-regulation of BDNF mRNA expression by activation of central mu opioid receptors. Neuroscience 2009; 161(1): 301-310.
219. Schwarzer S. 30 Years of Dynorphins-new insights on their functions in neuropsychiatric diseases. Pharmacol Ther 2009; 123(3): 353-370.
220. Rubaj A, Gustaw K, Zgodziski W, Kleinrok Z, Sieklucka-Dziuba M. The role of opioid receptors in hypoxic preconditioning against seizures in brain. Pharmacol Biochem Behav 2000; 67(1): 65-70.
221. Madar I, Lesser RP, Krauss G, et al. Imaging of delta- and muopioid receptors in temporal lobe epilepsy by positron emission tomography. Ann Neurol 1997; 41(3): 358-367.
222. Hammers A, Asselin M, Hinz R, et al. Upregulation of opioid receptor binding following spontaneous epileptic seizures. Brain 2007; 130(pt4): 1009-1016.
223. Honar H, Riazi K, Homayoun H, et al. Ultra-low dose naltrexone potentiates the anticonvulsant effect of low dose morphine on clonic seizures. Neuroscience 2004; 129(3): 733-742.
224. Negus SS, Gatch MB, Mello NK, Zhang X, Rice K. Behavioral effects of the delta-selective opioid agonist SNC80 and related compounds in rhesus monkeys. J Pharmacol Exp Ther 1998; 286(1): 362-375.
225. Jutkiewicz EM, Baladi MG, Folk JE, Rice KC, Woods JH. The convulsive and electroencephalographic changes produced by nonpeptidic delta-opioid agonists in rats: comparison with pentylenetetrazol. J Pharmacol Exp Ther 2006; 317(3): 1337-1348.
226. Jutkiewicz EM, Rice KC, Traynor JR, Woods JH. Separation of the convulsions and antidepressant-like effects produced by the deltaopioid agonist SNC80 in rats. Psychopharmacology (Berl) 2005; 182(4): 588-596.
227. Yamakawa K. Na+ channel gene mutations in epilepsy-the functional consequences. Epilepsy Res 2006; 70: S218-S222.
228. Xu R, Thomas EA, Jenkins M, et al. A childhood epilepsy mutation reveals a role for developmentally regulated splicing of a sodium channel. Mol Cell Neurosci 2007; 35(2): 292-301.
229. Agrawal N, Alonso A, Ragsdale DS. Increased persistent sodium currents in rat entorhinal cortex layer V neurons in a post-status epilepticus model of temporal lobe epilepsy. Epilepsia 2003; 44(12): 1601-1604.
230. Xia Y, Zhao P, Xue J, et al. Na+ channel expression and neuronal function in the Na+/H+ exchanger 1 null mutant mouse. J Neurophysiol 2003; 89(1): 229-236.
231. Zhao P, Ma MC, Qian H, Xia Y. Down-regulation of delta-opioid receptors in Na+/H+ exchanger 1 null mutant mouse brain with epilepsy. Neurosci Res 2005; 53(4): 442-446.
232. Remy S, Urban BW, Elger CE, Beck H. Anticonvulsant pharmacology of voltage-gated Na+ channels in hippocampal neurons of control and chronically epileptic rats. Eur J Neurosci 2003; 17(12): 2648-2658.
233. Armijo JA, Shushtarian M, Valdizan EM, Cuadrado A, de las Cuevas I, Adín J. Ion channels and epilepsy. Curr Pharm Des 2005; 11(15): 1975-2003.
234. Sheng WS, Hu S, Gekker G, Zhu S, Peterson PK, Chao CC. Immunomodulatory role of opioids in the central nervous system. Arch Immunol Ther Exp (Warsz) 1997; 45(5-6): 359-366.
235. Welters ID. Is immunomodulation by opioid drugs of clinical relevance? Curr Opin Anaesthesiol 2003; 16(5): 509-513.
236. Vallejo R, de Leon-Casasola O, Benyamin R. Opioid therapy and immunosuppression: a review. Am J Ther 2004; 11(5): 354-365.
237. Cheδdo MA, Idova GV. Role of serotonin receptors in the deltaopioid immunosuppression. Ross Fiziol Zh Im I M Sechenova 2010; 96(12): 1234-1240.
238. Eisenstein TK, Rahim RT, Feng P, Thingalaya N, Meissler JJ. Effects of opioid tolerance and withdrawal on the immune system. J Neuroimmune Pharmacol 2006; 1(3): 237-249.
239. Zou W, Guo Q, Wang E, Cai J, Cheng Z. Intrathecal morphine suppresses immune function in rats with inflammatory-induced pain. J Int Med Res 2007; 35(5): 626-636.
240. Jamali A, Bamdad T, Soleimanjahi H, Pakdel FG, Arefian E. Acute morphine administration reduces white blood cells' capability to induce innate resistance against HSV-1 infection in BALB/c mice. Neuroimmunomodulation 2007; 14(1): 16-23.
241. Carr D, Gebhart B, Paul D. Alpha adrenergic and mu-2 opioid receptors are involved in morphine-induced suppression of splenocyte natural killer activity. J Pharmacol Exp Ther 1993; 264(3): 1179-1186.
242. Welters ID, Menzebach A, Goumon Y, et al. Morphine suppresses complement receptor expression, phagocytosis, and respiratory burst in neutrophils by a nitric oxide and mu(3) opiate receptordependent mechanism. J Neuroimmunol 2000; 111(1-2): 139-145.
243. Grimm MC, Ben-Baruch A, Taub DD, et al. Opiates transdeactivate chemokine receptors: delta and mu opiate-receptor mediated heterologous desensitization. J Exp Med 1998; 188(2): 317-325.
244. Menzebach A, Hirsch J, Nost R, Mogk M, Hempelmann G, Welters ID. Morphine inhibits complement receptor expression, phagocytosis and oxidative burst by a nitric oxide dependent mechanism. Anasthesiol Intensivmed Notfallmed Schmerzther 2004; 39(4): 204-211.
245. Bai HB, Du JZ, Zheng XX. Beta-endorphin involved in the regulation of humoral immune function of rats during acute hypoxia. Acta Physiol Sinica 1999; 51(3): 258-262.
246. Parkhill AL, Bidlack JM. Reduction of lipopolysaccharide-induced interleukin-6 production by the kappa opioid U50, 488 in a mouse monocyte-like cell line. Int Immunopharmacol 2006; 6(6): 1013-1019.
247. Mahajan SD, Schwart SA, Aalinkeel R, Chawda RP, Sykes DE, Nair MP. Morphine modulates chemokine gene regulation in normal human astrocytes. Clin Immunol 2005; 115(3): 323-332.
248. Pello OM, Duthey B, García-Bernal D, et al. Opioids trigger a5-b1 integrin-mediated monocyte adhesion. J Immunol 2006; 176(3): 1675-1685.
249. Finley MJ, Happel CM, Kaminsky DE, Rogers TJ. Opioid and nociceptin receptors regulate cytokine and cytokine receptor expression. Cell Immunol 2008; 252(1-2): 146-154.
250. McCarthy L, Wetzel M, Sliker JK, Eisenstein TK, Rogers TJ. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend 2001; 62(2): 111-123.
251. Sharp BM, Keane WF, Suh HJ, Gekker G, Tsukayama D, Peterson PK. Opioid peptides rapidly stimulate superoxide production by human polymorphonuclear leukocytes and macrophages. Endocrinol 1985; 117(2): 793-795.
252. Chao CC, Hu S, Molitor TW, et al. Morphine potentiates transforming growth factor-beta release from human peripheral blood mononuclear cell cultures. J Pharmacol Exp Ther 1992; 262(1): 19-24.
253. Szabo I, Rojavin M, Bussiere JL, Eisenstein TK, Adler MW, Rogers TJ. Suppression of peritoneal macrophage phagocytosis of Candida albicans by opioids. J Pharmacol Exp Ther 1993; 267(2): 703-706.
254. Roy S, Cain KJ, Chapin RB, Charboneau RG, Barke RA. Morphine modulates NF kappa B activation in macrophages. Brochem Biophys Res Commun 1998; 245(2): 392-396.
255. Greeneltch KM, Haudenschild CC, Keegan AD, Shi Y. The opioid antagonist naltrexone blocks acute endotoxic shock by inhibiting tumor necrosis factor-alpha production. Brain Behav Immun 2004; 18(5): 476-484.
256. Alicea C, Belkowski S, Eisenstein TK, Adler MW, Rogers TJ. Inhibition of primary murine macrophage cytokine production in vitro following treatment with the kappa- opioid agonist U50,488H. J Neuroimmunol 1996; 64(1): 83-90.
257. Van Epps DE, Saland L. Beta-endorphin and met-enkephalin stimulate human peripheral blood mononuclear cell chemotaxis. J Immunol 1984; 132(6): 3046-3053.
258. Makman MH, Bilfinger TV, Stefano GB. Human granulocytes contain an opiate alkaloid-selective receptor mediating inhibition of cytokine-induced activation and chemotaxis. J Immunol 1995; 154(3): 1323-1330.
259. Ruff MR, Wahl SM, Mergenhagen S, Pert CB. Opiate receptormediated chemotaxis of human monocytes. Neuropeptides 1985; 5(4-6): 363-366.
260. Gosnell BA, Levine AS. Reward systems and food intake: role of opioids. Int J Obes (Lond) 2009; 33: S54-S58.
261. Marczak ED, Jinsmaa Y, Myers PH, et al. Orally administered HDmt-Tic-Lys-NH-CH2-Ph (MZ-2), a potent mu/delta-opioid receptor antagonist, regulates obese-related factors in mice. Eur J Pharmacol 2009; 616(1-3): 115-121.
262. Cooper PD, Dennis, SR, Woodman JD, Cowlings A, Donnelly C. Effect of opioid compounds on feeding and activity of the cockroach, Periplaneta americana. Comp Biochem Physiol C Toxicol Pharmacol 2010; 151(3): 298-302.
263. Obese FY, Whitlock BK, Steele BP, Buonomo FC, Sartin JL. Long-term feed intake regulation in sheep is mediated by opioid receptors. J Anim Sci 2007; 85(1): 11-17.
264. Barnes MJ, Holmes G, Primeaux SD, York DA, Bray GA. Increased expression of mu opioid receptors in animals susceptible to dietinduced obesity. Peptides 2006; 27(12): 3292-3298.
265. Zuberi AR, Townsend L, Patterson L, Zheng H, Berthoud HR. Increased adiposity on normal diet, but decreased susceptibility to diet-induced obesity in mu-opioid receptor-deficient mice. Eur J Pharmacol 2008; 585(1): 14-23.
266. Lenard NR, Zheng H, Berthoud HR. Chronic suppression of muopioid receptor signaling in the nucleus accumbens attenuates development of diet-induced obesity in rats. Int J Obes (Lond) 2010; 34(6): 1001-1010.
267. Czyzyk TA, Nogueiras R, Lockwood JF, et al. Kappa-Opioid receptors control the metabolic response to a high-energy diet in mice. FASEB J 2010; 24(4): 1151-1159.
268. Yeadon M, Kitchen I. Opioids and respiration. Prog Neurobiol 1989; 33(1): 1-16.
269. Pattinson KT. Opioids and the control of respiration. Br J Anaesth 2008; 100: 747-758.
270. Mansour A, Watson SJ. Anatomical distribution of opioid receptors in mammalians: an overview. In Herz, A. (ed.), Handbook of Experimental Pharmacology 1993; 104: 79-105.
271. Mutolo D, Bongianni F, Einum J, Dubuc R, Pantaleo T. Opioidinduced depression in the lamprey respiratory network. Neuroscience 2007; 150(3): 720-729.
272. Haji A, Takeda R, Okazaki M. Neuropharmacology of control of respiratory rhythm and pattern in mature mammals. Pharmacol Ther 2000; 86(3): 277-304.
273. Matthes HW, Smadja C, Valverde O, et al. Activity of the δ-receptor is partially reduced, whereas activity of the δ-receptor is maintained in mice lacking the δ-receptor. J Neurosci 1998; 18(18): 7285-7295.
274. Morin-Surun MP, Boudinot E, Dubois C, et al. Respiratory function in adult mice lacking the mu-opioid receptor: role of deltareceptors. Eur Neurobiol 2001; 13(9): 1703-1710.
275. Xia Y. Pressor effect of naloxone in acute experimental rabbits. Chin Pharmacol Bull 1989; 5: 162-164.
276. Lalley PM. Opioidergic and dopaminergic modulation of respiration. Respir Physiol Neurobiol 2008; 164(1-2): 160-167.
277. Forman LJ, Estilow S, Hock CE. Localization of beta-endorphin in the rat heart and modulation by testosterone. Proc Soc Exp Biol Med 1989; 190(3): 240-245.
278. Lang RE, Hermann K, Dietz R, et al. Evidence for the presence of enkephalins in the heart. Life Sci 1983; 32(4): 399-406.
279. Weihe E, McKnight AT, Corbett AD, Hartschuh W, Reinecke M, Kosterlitz HW. Characterization of opioid peptides in guinea-pig heart and skin. Life Sci 1983; 33(Suppl 1): 711-714.
280. Weihe E, McKnight AT, Corbett AD, Kosterlitz HW. Proenkephalin- and prodynorphin- derived opioid peptides in guinea-pig heart. Neuropeptides 1985; 5(4-6): 453-456.
281. Barron BA, Gu H, Gaugl JF, Caffrey JL. Screening for opioids in dog heart. J Mol Cell Cardiol 1992; 24(1): 67-77.
282. Spampinato S, Goldstein A. Immunoreactive dynorphin in rat tissues and plasma. Neuropeptides 1983; 3(3): 193-212.
283. Barron BA, Jones CE, Caffrey JL. Pericardial repair depresses canine cardiac catecholamines and met-enkephalin. Regul Pept 1995; 59(3): 313-320.
284. Eliasson T, Mannheimer C, Waagstein F, et al. Myocardial turnover of endogenous opioid and calcitonin-gene-related peptide in the humanheart and the effects of spinal cord stimulation on pacing-induced angina pectoris. Cardiology 1998; 89(3): 170-177.
285. Steele PA, Aromataris EC, Riederer BM. Endogenous opioid peptides in parasympathetic, sympathetic and sensory nerves in the guinea-pig heart. Cell Tissue Res 1996; 284(2): 331-339.
286. Hajrasouliha AR, Tavakoli S, Jabehdar-Maralani P, et al. Cholestatic liver disease modulates susceptibility to ischemia/reperfusion -induced arrhythmia, but not necrosis and hemodynamic instability: the role of endogenous opioid peptides. J Hepatol 2005; 43(3): 491-498.
287. Schindler CW, Graczyk Z, Gilman JP, et al. Effects of kappa opioid agonists alone and in combination with cocaine on heart rate and blood pressure in conscious squirrel monkeys. Eur J Pharmacol 2007; 576(1-3): 107-113.
288. Schultz JJ, Hsu AK, Gross GJ. Ischaemic preconditioning and morphine-induced cardioprotection involve the delta (δ)-opioid receptor in the intact rat heart. J Mol Cell Cardiol 1997; 29(8): 2187-2195.
289. Wu S, Li HY, Wong TM. Cardioprotection of Preconditioning by metabolic inhibition in the rat ventricular myocyte. Involvement of kappa-opioid receptor. Circ Res 1999; 84(12): 1388-1395.
290. Faden AI, Holaday JW. Opiate antagonists: a role in the treatment of hypovolemic shock. Science 1979; 205(4403): 317-318.
291. Holaday JW. Opiate antagonists in shock and trauma. Am J Emerg Med 1984; 2(1): 8-12.
292. Cavun S, Resch GE, Evec AD, Rapacon-Baker MM, Millington WR. Blockade of delta opioid receptors in the ventrolateral periaqueductal gray region inhibits the fall in arterial pressure evoked by hemorrhage. J Pharmacol Exp Ther 2001; 297(2): 612-619.
293. McBride SM, Smith-Sonneborn J, Oeltgen P, Flynn FW. Delta2 opioid receptor agonist facilitates mean arterial pressure recovery after hemorrhage in conscious rats. Shock 2005; 23(3): 264-268.
294. Boeuf B, Poirier V, Gauvin F, et al. Naloxone for shock. Cochrane Database Syst Rev 2003; 4: CD004443.
295. Gutkowska J, Jankowski M, Pawlak D, Mukaddam-Daher S, Izdebski J. The cardiovascular and renal effects of a highly potent mu-opioid receptor agonist, cyclo [Ne,Nb-carbonyl-D-Lys2,Dap5] enkephalinamide. Eur J Pharmacol 2004; 496(1-3): 167-174.
296. Wang J, Gao Q, Shen J, Ye TM, Xia Q. Kappa-opioid receptor mediates the cardioprotective effect of ischemic postconditioning. Zhejiang Da Xue Xue Bao Yi Xue Ban 2007; 36(1): 41-47.
297. Mao L, Wang JQ. Cardiovascular responses to microinjection of nociceptin and endomorphin-1 into the nucleus tractus solitarii in conscious rats. Neuroscience 2005; 132(4): 1009-1015.
298. Gross GJ. Role of opioids in acute and delayed preconditioning. J Mol Cell Cardiol 2003; 35(7): 709-718.
299. Gross ER, Hsu AK, Gross GJ. Opioid-induced cardioprotection occurs via glycogen synthase kinase beta inhibition during reperfusion in intact rat hearts. Circ Res 2004; 94(7): 960-966.
300. Peart JN, Patel HH, Gross GJ. Delta-opioid receptor activation mimics ischemic preconditioning in the canine heart. J Cardiovasc Pharmacol 2003; 42(1): 78-81.
301. Lasukova TV, Krylatov AV, Maslov LN, et al. Antiarrhythmic and cardioprotective effect of stimulation of delta1-opiate receptors in myocardial ischemia and reperfusion. Patol Fiziol Eksp Ter 2004; (3): 12-15.
302. Maslov LN, Lishmanov YB, Oeltgen PR, et al. Activation of peripheral delta2 opioid receptors increases cardiac tolerance to ischemia/reperfusion injury Involvement of protein kinase C, NOsynthase, KATP channels and the autonomic nervous system. Life Sci 2009; 84(19-20): 657-663.
303. Rong F, Peng Z, Ye MX, et al. Myocardial apoptosis and infarction after ischemia/reperfusion are attenuated by kappa-opioid receptor agonist. Arch Med Res 2009; 40(4): 227-234.
304. Zagon IS, Rahn KA, Bonneau RH, Turel AP, McLaughlin PJ. Opioid growth factor suppresses expression of experimental autoimmune encephalomyelitis. Brain Res 2010; 1310: 154-161.
305. Hill MP, Hille CJ, Brotchie JM. Delta-opioid receptor agonists as a therapeutic approach in Parkinson's disease. Drug News Perspect 2000; 13(5): 261-268.
306. Mabrouk OS, Volta M, Marti M, Morari M. Stimulation of delta opioid receptors located in substantia nigra reticulata but not globus pallidus or striatum restores motor activity in 6-hydroxydopamine lesioned rats: new insights into the role of delta receptors in parkinsonism. J Neurochem 2008; 107(6): 1647-1659.
307. Ikeda K, Yoshikawa S, Kurokawa, T, Yuzawa N, Nakao K, Mochizuki H. TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease. Eur J Pharmacol 2009; 620(1-3): 42-48.
308. Wikstrom B, Gellert R, Ladefoged SD, et al. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebocontrolled clinical studies. J Am Soc Nephrol 2005; 16(12): 3742-3747.
309. Kakinohana M. Spinal cord protection and opioids. Masui 2007; 56(3): 298-304.
310. Iselin-Chaves IA, Grötzsch H, Besson M, Burkhard PR, Savoldelli GL. Naloxone- responsive acute dystonia and parkinsonism following general anaesthesia. Anaesthesia 2009; 64(12): 1359-1362.
311. Zesiewicz TA, Hauser RA, Freeman A, Sullivan KL, Miller AM, Halim T. Fentanyl-induced bradykinesia and rigidity after deep brain stimulation in a patient with Parkinson disease. Clin Neuropharmacol 2009; 32(1): 48-50.
312. Koprich JB, Fox SH, Johnston TH, et al. The selective mu-opioid receptor antagonist, ADC5510, reduces L-DODA induced dyskinesia in the MPTP macaque model of Parkinson's disease. Abstract of International Narcotics Research Conference 2010; page 85.
313. Ammon-Treiber S, Stolze D, Schröder H, Loh H, Höllt V. Effects of opioid antagonists and morphine in a hippocampal hypoxia/hypoglycemia model. Neuropharmacology 2005; 49(8): 1160-1169.
314. Ammon-Treiber S, Stolze D, Ḧllt V. Differential effects of muopioid receptor agonists in a hippocampal hypoxia/hypoglycemia model. Brain Res 2007; 1183: 60-65.
315. San-Emeterio EP, Hurlé MA. Modulation of brain apoptosisrelated proteins by the opioid antagonist naltrexone in mice. Neurosci Lett 2006; 403(3): 276-279.